Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

BioInvent's Competitors, Revenue, Number of Employees, Funding and Acquisitions

BioInvent is engaged in discovery and development of antibody drugs for the treatment of cancer. Read more

Martin Welschof's photo - President & CEO of BioInvent

President & CEO

Martin Welschof

CEO Approval Rating

92/100

Founded:

1996

Status:

PublicOtherBINV

SIC Code:

2836 NAICS listing »

Annual Revenue
Employees
Sector
Biotechnology
Headquarters

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in BioInvent's competitive set are Orexo, Phenex, Active Biotech, NeuroVive, Pfizer, Novartis, Amgen, Allenex, AstraZeneca and Beactica. Together they have raised over 4.0B between their estimated 286.7K employees. BioInvent has 59 employees and is ranked 7th among it's top 10 competitors. The top 10 competitors average 26,382.

Orexo is one of BioInvent's top rivals. Orexo is a Public company that was founded in 1995 in Uppsala, Uppsala län. Orexo competes in the Pharmaceuticals industry. Compared to BioInvent, Orexo has 69 more employees.

Phenex is seen as one of BioInvent's biggest rivals. Phenex was founded in 2002 in Ludwigshafen, Rhineland-Palatinate. Like BioInvent, Phenex also works within the Biotechnology field. Phenex generates $410.3K more revenue than BioInvent.

Active Biotech is one of BioInvent's top competitors. Active Biotech was founded in 1996, and its headquarters is in Lund, Skåne län. Like BioInvent, Active Biotech also operates in the Biotechnology sector. Active Biotech has 42 fewer employees than BioInvent.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Pfizer a competitor of BioInvent?

I don't know

Explore companies in similar locations and sectors

Trending News for BioInvent and BioInvent's Competitors

August 10, 2020

FinanzNachrichten

Orexo receives paragraph IV Notice Letter for ZUBSOLV in the US

UPPSALA, Sweden, Aug. 10, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today ann... See more »

August 12, 2020

Prime Times

Pfizer-BioNTech Potential Covid-19 Vaccine Induces Immune Response in Early-phase Clinical Trial: Study

A COVID-19 vaccine candidate co-developed by the pharmaceutical giant Pfizer and the German biotech c... See more »

August 11, 2020

The Pharma Letter

Daiichi Sankyo and AstraZeneca team up to trial drug combo in NSCLC

Japan's Daiichi Sankyo has entered into a clinical trial collaboration with UK-based AstraZeneca to..... See more »

Quarterly and Annual Revenue

Coming soon for BioInvent!

Annual Revenue

$7.5M

BioInvent's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 14.7B.

Acquisitions

No recent acquisitions found related to BioInvent

BioInvent Funding History

$6M

Since BioInvent was founded in 1996, it has participated in 1 round of funding. In total BioInvent has raised $6.0M. BioInvent's funding round was on Dec 2016 for a total of $6.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Dec 2016
$6M

Pfizer

Total Funding: $6M

Since BioInvent was founded in 1996, it has participated in 1 round of funding. In total BioInvent has raised $6.0M. BioInvent's funding round was on Dec 2016 for a total of $6.0M

Investments

No recent investments found related to BioInvent

BioInvent News

July 1, 2020The Pharma Letter

BioInvent and Pfizer extend antibody research collaboration

Swedish immuno-oncology firm BioInvent and New York pharma major Pfizer have extended their ongoing c... See more »
June 25, 2020Pharmabiz

BioInvent begins phase I/IIa trial of BI1206 in combo with Keytruda to treat solid tumors

BioInvent International AB, a biotech company focused on the discovery and development of novel and f... See more »
June 22, 2020FinanzNachrichten

BioInvent Presents Proof-of-concept Data for two TNFR2-targeting Antibodies

- Proof of concept for both agonistic and ligand-blocking TNFR2 targeting antibodies - Both antibodie... See more »
June 22, 2020BioSpace

Transgene's and BioInvent's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models

Proof of concept for novel oncolytic virus with differentiated anti-CTLA4 antibody Significant antitu... See more »
June 18, 2020MarketScreener

Proposal for a new Board member to be elected at the Extraordinary General Meeting on July 3, 2020

(marketscreener.com) Further to the investment made by HBM Healthcare Investments ltd. in the directe... See more »
June 9, 2020MarketScreener

Notice to Extraordinary General Meeting in BioInvent International AB

(marketscreener.com) The shareholders of BioInvent International AB , Reg. No 556537-7263, are hereby... See more »
June 9, 2020MarketScreener

BioInvent successfully completes a directed share issue of approximately SEK 487 million (approximately EUR 47 million)

(marketscreener.com) You are about to view web pages that are not intended for release, publication o... See more »

BioInvent Press Releases

July 10, 2017Blackbird

ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement

LEUVEN, Belgium, July 10, 2017 /PRNewswire/ --ThromboGenics NV (Euronext Brussels: THR) and BioInvent... See more »
February 22, 2017Blackbird

LifeSci Capital Initiates Coverage of BioInvent

See more »
August 11, 2016NewsMaker

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or CD134 or TNFRSF4) Therapeutics Companies Pipeline R

Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated... See more »
August 11, 2016Business Wire

MacroGenics, Xencor, BioInvent International - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Low Affinity Immunog... See more »
June 16, 2016Business Wire

Global Tumor Necrosis Factor Receptor Superfamily Member 9 (T-Cell Antigen 4-1BB Homolog or T-Cell Antigen ILA or CD137 or TNFRSF9) Pipeline Review of 4 Therapeutics Companies 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Tumor Necrosis Facto... See more »
May 9, 2016M2 PressWIRE

BioInvent announces increase in shareholding by board director

See more »
May 2, 2016M2 PressWIRE

BioInvent reports increase in number of shares and votes

See more »

Headquarters

Sölvegatan 41 The Gamma Building

Lund, Skåne län22362

46-46-286-85-50

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

BioInvent is engaged in discovery and development of antibody drugs for the treatment of cancer. BioInvent was founded in 1996. BioInvent's headquarters is located in Lund, Skåne län, SE 22362. It has raised 6.0M in 1 round. The latest round was in De...

CEO

BioInvent's President & CEO, Martin Welschof, currently has an approval rating of 92%. BioInvent's primary competitors are Orexo, Phenex & Active Biotech.

Website

bioinvent.com

Frequently Asked Questions about BioInvent

  1. When was BioInvent founded?

    BioInvent was founded in 1996

  2. Who is BioInvent's CEO?

    BioInvent's CEO is Martin Welschof

  3. How much revenue does BioInvent generate?

    BioInvent generates $7.5M in revenue

  4. How much funding does BioInvent have?

    BioInvent has historically raised $6M in funding

  1. Where is BioInvent's headquarters?

    BioInvent's headquarters is in Lund Skåne län, SE

  2. How many employees does BioInvent have?

    BioInvent has 59 employees

  3. What sector does BioInvent operate in?

    BioInvent is in Biotechnology

  4. Who are BioInvent's competitors?

    BioInvent's top competitors are Orexo, Phenex, Active Biotech
Stay up-to-date with the latest news on BioInvent